In the field of biotech, Thermo Fisher Scientific (TMO) has seen an interesting mix of events recently. The firm's Chief Operating Officer made a significant move by selling 22,046 shares. The company experienced solid Q3 performance and the recent share price gains prompted reassessment of its valuation. HSBC upgraded TMO and several new investments and stock adjustments were made by entities like Stenger Family Office LLC, Michel Lagarde and Mirabella Financial Services. The Asia Bioprocessing Tri-Hub expansion has the potential to reshape Thermo Fisher's narrative. Insider selling of stock was also witnessed with EVP selling 6,912 shares. Thermo Fisher's Asia Bioprocessing network might change the case for investing in them. There is a significant increase in TMO's rating by HSBC and its valuation was reassessed after a 10% monthly share price surge. TMO also raised €2.1 Billion through floating and fixed-rate senior notes. With their recent developments, TMO seems to be on a strong financial path.
Thermo Fisher Scientific TMO News Analytics from Sat, 26 Jul 2025 07:00:00 GMT to Sat, 06 Dec 2025 22:46:12 GMT -
Rating 8
